Edwards Lifesciences (EW) Valuation Re-rating: A Bullish Case Amidst Structural Shifts

Strategic Pivot and Market Position

Edwards Lifesciences Corporation (EW) has successfully transitioned into a pure-play leader in structural heart disease. This strategic evolution followed the divestiture of its Critical Care business to Becton, Dickinson and Company for $4.2 billion in cash. While this transaction removed approximately 20% of the company's 2023 EBITDA base, the move has been effectively offset by rapid expansion in high-growth segments.

The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment is now a primary growth engine, expanding over 50% year-over-year. Simultaneously, the core Transcatheter Aortic Valve Replacement (TAVR) franchise remains robust, generating over $4.5 billion in annual revenue with growth exceeding 12%. This division continues to offer scalability, particularly as indications expand to include asymptomatic and moderate aortic stenosis patients.

Valuation and Financial Fundamentals

As of March 16th, Edwards Lifesciences shares were trading at $83.92. The stock recently experienced a pullback from recent highs of $87, settling around $78, which analysts view as an attractive entry point. Key financial metrics supporting this thesis include:

• Gross Margins: 78%
• Cash Position: $3.8 billion on the balance sheet
• Valuation Multiples: Trailing P/E of 46.17 and forward P/E of 28.49.
• EV/NTM EBITDA: Approximately 21.3x, which sits below its historical average of 26x.

The company is positioned for an expected EBITDA Compound Annual Growth Rate (CAGR) of 10–11%. Combined with ongoing share repurchases and disciplined capital allocation, the current valuation suggests room for multiple expansion alongside earnings growth. In a favorable scenario, these factors could drive compelling double-digit annualized returns.

Historical Context and Hedge Fund Sentiment

This bullish perspective aligns with previous analysis from January 2025 by Natan, which highlighted EW's leadership in TAVR and margin resilience. Since that coverage, the stock has appreciated by approximately 14.12%. Federico Torre's current thesis echoes these points but places specific emphasis on valuation re-rating and balance sheet strength.

Regarding institutional interest, Edwards Lifesciences is not currently listed among the 30 Most Popular Stocks Among Hedge Funds. Database records indicate that 64 hedge fund portfolios held EW at the end of the third quarter, a slight decrease from 65 in the previous quarter. While acknowledging the company's potential, some analysts note that AI stocks may offer higher returns within shorter timeframes.

Context

This article synthesizes a bullish investment thesis for Edwards Lifesciences (EW) published by Federico Torre of Torre Financial Newsletter on Substack. The analysis focuses on the company's strategic shift away from critical care toward structural heart therapies, evaluating whether current market valuations offer an opportunity for capital appreciation given the strong growth in TMTT and stable TAVR revenues.

Takeaway

Edwards Lifesciences presents a compelling investment case driven by its transition to a pure-play structural heart leader, with TMTT growth exceeding 50% YoY. Trading at a valuation multiple (21.3x EV/NTM EBITDA) below its historical average of 26x, the stock offers potential for double-digit returns through both earnings expansion and multiple re-rating, supported by strong fundamentals including $3.8 billion in cash and 78% gross margins.